Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17934931 | 1.00 | AGER (0.51) | AGERFDPSCYP19A1 | |
| Hydrochloric Acid SCHEMBL411541 | 0.98 | AGER (0.50) | AGERFDPSCYP19A1 | |
| SCHEMBL10247560 | 0.87 | AGER (0.62) | AGERFDPSCYP19A1 | |
| Hydrochloric Acid SCHEMBL1775858 | 0.85 | AGER (0.60) | AGERFDPSCYP19A1 | |
| SCHEMBL6306204 | 0.82 | TBXAS1 (0.51) | AGERFDPS | |
| SCHEMBL15187295 | 0.82 | TBXAS1 (0.51) | AGERFDPS | |
| SCHEMBL15187342 | 0.82 | TBXAS1 (0.51) | AGERFDPS | |
| SCHEMBL10730735 | 0.82 | AGER (0.53) | AGERFDPSCYP19A1 | |
| SCHEMBL11292777 | 0.82 | AGER (0.53) | AGERFDPSCYP19A1 | |
| SCHEMBL1585079 | 0.82 | AGER (0.53) | AGERFDPSCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173740-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | Osta Biotechnologies (CA) | 2010-04-14 | — | — | EP | claimed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | claimed |
| EP-0025948-B1 | ACYLATED IMIDAZOLYL-GAMMA-FLUOROPINACOLYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BAYER AG (DE) | 1983-03-02 | — | — | EP | claimed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| EP-0111384-B1 | THIOKETAL SUBSTITUTED N-ALKYL IMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1987-04-22 | — | — | EP | disclosed |
| EP-0104300-B1 | DIAZOLYL ALKANOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIMYCOTIC AGENTS | BAYER AG (DE) | 1986-03-26 | — | — | EP | disclosed |
| US-4518607-A | FUNGICIDES, BACXTERICIDES AND ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1985-05-21 | — | — | US | disclosed |
| US-4489087-A | Spermicidal thioketal substituted N-alkyl imidazoles | SYNTEX (U.S.A.) INC. (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0111384-A1 | Thioketal substituted N-alkyl imidazoles and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1984-06-20 | — | — | EP | disclosed |
| EP-0104300-A1 | Diazolyl alkanoles, process for their preparation and their use as antimycotic agents | BAYER AG (DE) | 1984-04-04 | — | — | EP | disclosed |
| US-4415586-A | FUNGICIDES; MICROBIOCIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| US-4229459-A | Combating fungi with 1-azol-1-yl-1-phenoxy-2-alkane ethers | BAYER AKTIENGESELLSCHAFT (DE) | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | AGER 2741/4885FDPS 1728/4885CYP19A1 884/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | AGER 2555/4885FDPS 1078/4885CYP19A1 641/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | AGER 2555/4885FDPS 1078/4885CYP19A1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.